TrialCirculation. Heart failure2026

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.

Ahmad Masri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.